CDC, FDA recommend pause in Johnson & Johnson COVID vaccine after reports of rare blood clots
he federal agencies said they were investigating clots in six women in the days after they received the vaccination
The CDC and FDA on Tuesday recommended a "pause" in administering single-dose Johnson & Johnson COVID-19 vaccine in the United State until they can fully investigate reports of potentially dangerous blood clots.
In a joint statement, the federal agencies said they were investigating clots in six women in the days after they received the vaccination, according to the Associated Press.
The CDC’s Advisory Committee on Immunization Practices will meet Wednesday to discuss the cases, and the FDA has also launched an investigation of the cases.
“Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution,” Dr. Anne Schuchat, principal deputy director of the CDC and Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research said in a joint statement, obtained by the wire service.